Overview

Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma

Status:
Completed
Trial end date:
2019-10-11
Target enrollment:
Participant gender:
Summary
This is a prospective study to evaluate the hypothesis that platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy is associated with improved maximal surgical cytoreduction rates, comparable survival, decreased morbidity, and increased quality of life in patients with International Federation of Gynecologic Oncology stages IIIC and IV ovarian, primary peritoneal, or fallopian tube cancer when compared to historical controls and to evaluate the hypothesis that cancer induced inflammation is a predictor of poor prognosis and response to therapy in this group of ovarian cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
Rachel Miller